Alpha 2.0
Login Register
» Authors » Ron L Akehurst

Ron L Akehurst

Explore the profile of Ron L Akehurst including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 266
Followers 0
Related Specialties
Pharmacology
Public Health
Biomedical Engineering
Top 10 Co-Authors
Allan J Wailoo
Nicola Mason
Nicholas R Latimer
Maria Platts
Jason Madan
Nigel Mathers
Michael J Crowther
Anne Morgan
George Jessen
Eva Kaltenthaler
Published In
Value Health
Pharmacoeconomics
Health Expect
Med Decis Making
BMC Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands
Schurer M, Matthijsse S, Vossen C, van Keep M, Horscroft J, Chapman A, et al.
Value Health . 2022 Jan; 25(1):91-103. PMID: 35031104
Objectives: Since 2015, Zorginstituut Nederland (ZIN) has linked disease severity ranges of 0.10 to 0.40, 0.41 to 0.70, and 0.71 to 1.00 with willingness-to-pay (WTP) reference values of €20 000,...
2.
Benefits, Challenges and Potential Strategies of Open Source Health Economic Models
Dunlop W, Mason N, Kenworthy J, Akehurst R
Pharmacoeconomics . 2016 Dec; 35(1):125-128. PMID: 27928759
No abstract available.
3.
Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations
Latimer N, Abrams K, Lambert P, Crowther M, Wailoo A, Morden J, et al.
Med Decis Making . 2014 Jan; 34(3):387-402. PMID: 24449433
Background: Treatment switching commonly occurs in clinical trials of novel interventions in the advanced or metastatic cancer setting. However, methods to adjust for switching have been used inconsistently and potentially...
4.
Choosing vs. allocating: discrete choice experiments and constant-sum paired comparisons for the elicitation of societal preferences
Skedgel C, Wailoo A, Akehurst R
Health Expect . 2013 Jun; 18(5):1227-40. PMID: 23758539
Background: There is growing evidence of a reluctance to allocate health care solely on the basis of maximizing quality-adjusted life years (QALYs). Stated preference methods can be used to elicit...
5.
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
Cooper K, Madan J, Whyte S, Stevenson M, Akehurst R
BMC Cancer . 2011 Sep; 11:404. PMID: 21943360
Background: Febrile neutropenia (FN) occurs following myelosuppressive chemotherapy and is associated with morbidity, mortality, costs, and chemotherapy reductions and delays. Granulocyte colony-stimulating factors (G-CSFs) stimulate neutrophil production and may reduce...
6.
Cost-effectiveness of low-level heat wrap therapy for low back pain
Lloyd A, Scott D, Akehurst R, Lurie-Luke E, Jessen G
Value Health . 2004 Sep; 7(4):413-22. PMID: 15449633
Objectives: To evaluate the cost-effectiveness and budget impact of a new heat wrap therapy for low back pain compared to paracetamol and ibuprofen from the perspective of the UK National...
7.
Making decisions on technology availability in the British National Health Service--why we need reliable models
Akehurst R
Value Health . 2003 Jan; 6(1):3-5. PMID: 12535232
No abstract available.
8.
Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting
Akehurst R, Brazier J, Mathers N, OKeefe C, Kaltenthaler E, Morgan A, et al.
Pharmacoeconomics . 2002 Jul; 20(7):455-62. PMID: 12093301
Objectives: To identify the impact of irritable bowel syndrome (IBS) on health-related quality of life (HR-QOL), time off work and the utilisation and cost of health services. Design: A case-control...